Alzheimer's stem cell trial pulled before it even started

NCT ID NCT04228666

Terminated Disease control Sponsor: Hope Biosciences LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial aimed to test the safety of giving four infusions of a patient's own fat-derived stem cells to people with early Alzheimer's disease. It was designed for adults aged 50-85 with mild cognitive impairment or early-stage Alzheimer's. However, the study was withdrawn before enrolling any participants, so no data on safety or effectiveness were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
What this could lead to: If this approach had worked, it could have pointed toward a way to slow or manage Alzheimer's disease progression using a patient's own stem cells.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. Stem cell treatments for Alzheimer's are still highly experimental, with uncertain benefits and potential risks like infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Show contact details

Locations

Clinical Trial Network

Houston, Texas, 77074, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.